Royalty Revenue from Stivarga

9 Months Ended

Sep. 30, 2012

Royalty Revenue from Stivarga

Royalty Revenue from Stivarga

Note 4. Royalty Revenue from Stivarga

On September 27, 2012, we announced that Bayer HealthCare received accelerated approval in the United States for Stivarga® (regorafenib) tablets, an oral multikinase inhibitor, indicated for the treatment of metastatic colorectal cancer, in patients whose disease has progressed despite prior treatment (including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy); and Bayer also submitted a Supplemental New Drug Application, or sNDA, for regorabenib for the treatment of gastrointestinal stromal tumors, or GIST, in patients whose disease has progressed despite prior treatment. Onyx is co-promoting Stivarga in the United States with Bayer. Onyx is entitled to receive a twenty percent royalty on global net sales of Stivarga in oncology.